Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and females aged 18-50 with symptomatic eosinophilic esophagitis
Female subjects must be women of non child bearing potential.
Elimination diet must have been tried.
Treatment for at least two months prior to enrollment on a protocol pump inhibitor .
Appropriate contraception must be used by males, (e.g., spermicidal gel plus condom)
Must be able to communicate well with the investigator, to understand and comply with the requirements of the study.
Understand and sign the written informed consent.
You may not be if
Have received corticosteroids within 3 months before starting the study for any symptoms.
Any other eosinophilic disorders.
History of clinical schistosomiasis, or having travelled within the preceding 6 months to an area with endemic schistosomiasis, including but not limited to Southeast and Southwest Asia, South America and Africa. Travel to these areas must not be planned for at least 6 months after the last dose.
Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing.
History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.
History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during the screening.
Clareo Health | Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
